A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Trial Profile

A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Gemcitabine (Primary) ; MSB 0011359C (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Apr 2018 Planned initiation date changed from 16 Apr 2018 to 18 Apr 2018.
    • 10 Apr 2018 Planned initiation date changed from 27 Mar 2018 to 16 Apr 2018.
    • 22 Mar 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 7 Mar 2018 to 27 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top